Dr Michael Sullivan

  • Clinical Research Fellow (Institute of Cardiovascular & Medical Sciences)

Biography

Dr Michael Sullivan is a Specialist Trainee in Renal Medicine and a Clinical Research Fellow at the Institute of Cardiovascular and Medical Sciences.
 
Michael graduated from the University of Aberdeen with MBChB (with honours) in 2011 . He completed Membership of the Royal College of Physicians in 2015 and an MSc in Internal Medicine (with distinction) in 2016. He obtained his Specialist Certificate in Renal Medicine in 2019.
 
Michael works as a Specialist Registrar at the Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital.

Research interests

In 2020 Michael was awarded a Medical Research Council Clinical Research Training Fellowship entitled "Interrogating disease clusters, multimorbidity and adverse outcomes in chronic kidney disease". This project seeks to understand the health problems faced by people with kidney disease and multiple long-term health conditions.
 
He is interested in using large cohorts to study people with kidney disease and their heightened risk of problems such as cardiovascular disease.

Publications

List by: Type | Date

Jump to: 2022 | 2021 | 2020
Number of items: 8.

2022

Sullivan, M. K. and Mark, P. B. (2022) Daprodustat in renal anaemia: changing the response to cellular hypoxia, but is it a game changer? Cardiovascular Research, (doi: 10.1093/cvr/cvac067) (PMID:35639861) (Early Online Publication)

Sullivan, M. K. et al. (2022) Acute kidney injury in patients hospitalised with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 37(2), pp. 271-284. (doi: 10.1093/ndt/gfab303) (PMID:34661677) (PMCID:PMC8788218)

2021

Sullivan, M. K. et al. (2021) Hospitalisation events in people with chronic kidney disease as a component of multimorbidity: parallel cohort studies in research and routine care settings. BMC Medicine, 19, 278. (doi: 10.1186/s12916-021-02147-6)

Sullivan, M. K. et al. (2021) Multimorbidity and the risk of major adverse kidney events: findings from the UK Biobank cohort. Clinical Kidney Journal, 14(11), pp. 2409-2419. (doi: 10.1093/ckj/sfab079) (PMCID:PMC8573008)

Lees, J. S. et al. (2021) Kidney function and cancer risk: an analysis using creatinine and cystatin C in a cohort study. EClinicalMedicine, 38, 101030. (doi: 10.1016/j.eclinm.2021.101030) (PMID:34505030)

Drake, T. M. et al. (2021) Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), pp. 223-237. (doi: 10.1016/S0140-6736(21)00799-6) (PMID:34274064) (PMCID:PMC8285118)

2020

McQueenie, R. et al. (2020) Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS ONE, 15(8), e0238091. (doi: 10.1371/journal.pone.0238091) (PMID:32817712) (PMCID:PMC7440632)

Sullivan, M. , Rankin, A. , Jani, B. D. , Mair, F. S. and Mark, P. B. (2020) Associations between multimorbidity and adverse clinical outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open, 10, e038401. (doi: 10.1136/bmjopen-2020-038401) (PMID:32606067) (PMCID:PMC7328898)

This list was generated on Wed Jun 29 13:12:54 2022 BST.
Jump to: Articles
Number of items: 8.

Articles

Sullivan, M. K. and Mark, P. B. (2022) Daprodustat in renal anaemia: changing the response to cellular hypoxia, but is it a game changer? Cardiovascular Research, (doi: 10.1093/cvr/cvac067) (PMID:35639861) (Early Online Publication)

Sullivan, M. K. et al. (2022) Acute kidney injury in patients hospitalised with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 37(2), pp. 271-284. (doi: 10.1093/ndt/gfab303) (PMID:34661677) (PMCID:PMC8788218)

Sullivan, M. K. et al. (2021) Hospitalisation events in people with chronic kidney disease as a component of multimorbidity: parallel cohort studies in research and routine care settings. BMC Medicine, 19, 278. (doi: 10.1186/s12916-021-02147-6)

Sullivan, M. K. et al. (2021) Multimorbidity and the risk of major adverse kidney events: findings from the UK Biobank cohort. Clinical Kidney Journal, 14(11), pp. 2409-2419. (doi: 10.1093/ckj/sfab079) (PMCID:PMC8573008)

Lees, J. S. et al. (2021) Kidney function and cancer risk: an analysis using creatinine and cystatin C in a cohort study. EClinicalMedicine, 38, 101030. (doi: 10.1016/j.eclinm.2021.101030) (PMID:34505030)

Drake, T. M. et al. (2021) Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), pp. 223-237. (doi: 10.1016/S0140-6736(21)00799-6) (PMID:34274064) (PMCID:PMC8285118)

McQueenie, R. et al. (2020) Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS ONE, 15(8), e0238091. (doi: 10.1371/journal.pone.0238091) (PMID:32817712) (PMCID:PMC7440632)

Sullivan, M. , Rankin, A. , Jani, B. D. , Mair, F. S. and Mark, P. B. (2020) Associations between multimorbidity and adverse clinical outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open, 10, e038401. (doi: 10.1136/bmjopen-2020-038401) (PMID:32606067) (PMCID:PMC7328898)

This list was generated on Wed Jun 29 13:12:54 2022 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Tackling the challenge of multimorbidity in chronic kidney disease

    2020 - 2022